COMPANY

Aro Biotherapeutics

HQ: Philadelphia, PA source · arobiotx.com ↗

Aro Biotherapeutics is a biotechnology company the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. From company website Source · Oct 12, 2026

Keywords: Late Onset Pompe Disease

Location: Philadelphia, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $41.5M · announced Nov 28, 2023 Company release ↗
Source quote
- Nov 28, 2023 · Company release ↗
  “Philadelphia, PA, November 28, 2023 --- Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round”

Raises announced in these releases: $41.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 28, 2023 Raise Series B · $41.5M source ↗
Oct 19, 2023 Trial start Early phase 1: Study to Assess the Safety, Tolerability, PK and PD of ABX1100 source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06109948	Study to Assess the Safety, Tolerability, PK and PD of ABX1100	Early phase 1	Completed	Oct 19, 2023	Feb 13, 2026 (actual)